The estimated Net Worth of Filip Dubovsky is at least $1.65 Million dollars as of 17 June 2024. Filip Dubovsky owns over 13,904 units of Novavax stock worth over $989,554 and over the last few years he sold NVAX stock worth over $657,637. In addition, he makes $0 as Senior Vice President and Chief Medical Officer at Novavax.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Filip Dubovsky NVAX stock SEC Form 4 insiders trading
Filip has made over 8 trades of the Novavax stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 13,904 units of NVAX stock worth $85,927 on 17 June 2024.
The largest trade he's ever made was selling 47,312 units of Novavax stock on 14 May 2024 worth over $657,637. On average, Filip trades about 11,896 units every 41 days since 2023. As of 17 June 2024 he still owns at least 80,517 units of Novavax stock.
You can see the complete history of Filip Dubovsky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Filip Dubovsky biography
Dr. Filip Dubovsky M.D. serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Dubovsky brings more than 20 years of infectious disease experience to Novavax. He joins Novavax from AstraZeneca, where he was Head of Clinical Engagement and Policy and Deputy Chief Medical Officer for clinical affairs. He joined MedImmune, the global biologics arm of AstraZeneca, where he oversaw the clinical development of early and late-stage infectious disease and vaccine assets. Previously, he created and managed a portfolio of 25 malaria vaccine candidates spanning early candidate optimization to Phase 3 clinical studies at PATH's Malaria Vaccine Initiative. He has co-authored more than 50 peer-reviewed scientific publications and currently sits on the Board of Directors of the Sabin Institute. Dr. Dubovsky earned his Master of Public Health degree from Johns Hopkins University and his Doctor of Medicine degree from the University of Alabama. He completed his pediatric training at Stanford University, his pediatric infectious disease fellowship at the Center for Vaccine Development at the University of Maryland, and his preventive medicine training at Johns Hopkins University.
What's Filip Dubovsky's mailing address?
Filip's mailing address filed with the SEC is 700 QUINCE ORCHARD ROAD, , GAITHERSBURG, MD, 20878.
Insiders trading at Novavax
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi, and Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
What does Novavax do?
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
What does Novavax's logo look like?
Complete history of Filip Dubovsky stock trades at Novavax
Novavax executives and stock owners
Novavax executives and other stock owners filed with the SEC include:
-
Stanley Erck,
President, Chief Executive Officer, Director -
Gregory Glenn,
President, Research and Development -
John Trizzino,
Executive Vice President, Chief Commercial Officer, Chief Business Officer -
John Herrmann,
Executive Vice President, Chief Legal Officer -
Stanley Charles Erck,
Pres, CEO & Director -
Dr. Gregory M. Glenn,
Pres of R&D -
John Joseph Trizzino B.S., M.B.A.,
Exec. VP and Chief Bus. & Commercial Officer -
John A. Herrmann III,
Exec. VP, Chief Legal Officer & Corp. Sec. -
James Young,
Independent Chairman of the Board -
Michael McManus,
Independent Director -
Gary Evans,
Independent Director -
Richard Douglas,
Independent Director -
Rachel King,
Independent Director -
Gregory Covino,
Chief Financial Officer, Executive Vice President -
David Mott,
Independent Director -
Rajiv Modi,
Director -
Gregg Alton,
Director -
Brian Webb,
Senior Vice President - Manufacturing -
Brian Rosen,
Senior Vice President - Commercial Strategy -
Jody Lichaa,
Senior Vice President - Quality Assurance -
Filip Dubovsky,
Senior Vice President, Chief Medical Officer -
Silvia Taylor,
Senior Vice President of Investor Relations and Corporate Affairs -
Frank Czworka,
Senior Vice President - Global Sales -
Ben Machielse,
Executive Vice President - CMC -
Jill Hoyt,
Chief Human Resource Officer, Executive Vice President -
Troy Morgan Esq., J.D.,
Sr. VP & Chief Compliance Officer -
Troy Morgan Esq.,
Sr. VP & Chief Compliance Officer -
Silvia Taylor M.B.A., MBA,
Sr. VP of Global Corp. Affairs & Investor Relations -
Biegie Lee,
Sr. VP & Chief Information Officer -
Dr. Gale E. Smith,
Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist -
Richard P. Crowley,
Exec. VP & COO -
James Patrick Kelly C.F.A.,
Exec. VP, CFO & Treasurer -
Richard J Rodgers,
-
Margaret G Mcglynn,
-
Gail Boudreaux,
Director -
Barclay A Phillips,
SVP, Chief Financial Officer -
Mark J Casey,
EVP, CLO & Corporate Secretary -
Mitchell J Kelly,
Director -
Susan B Bayh,
Director -
Ford R Lynch,
Sr. VP Marketing and Sales -
John A Lambert,
Director -
Thomas Scott Johnston,
Vice President, Strategy -
Pharmaceuticals Inc King,
10% owner -
John O Jr Marsh,
Director -
Strategic Investments Llcgr...,
-
Denis M Odonnell,
Director -
Ronlad H Walker,
Director -
Frederick W Driscoll,
VP, CFO & Treasurer -
James B Tananbaum,
Director -
Evdoxia E Kopsidas,
Dir.Fin.,Int.Princ.Acctg.Off. -
Jim Robinson,
VP,Technical & Qual. Operation -
D Craig Wright,
Chief Scientific Officer -
Patricia Hall,
Chief Accounting Officer -
Nelson M Sims,
President/CEO -
Raymond Joseph Hage,
VP - Business Development -
Russell P Wilson,
SVP, Business Development -
Len F Stigliano,
VP, CFO and Treasurer -
Ann P Mcgeehan,
General Counsel/Secr -
Timothy Jon Hahn,
SVP, Manufacturing & PD -
Pharmaceuticals Ltd Satelli...,
-
Dennis W Genge,
VP, Treasurer,CFO -
J Michael Md Lazarus,
Director -
Penny Heaton,
Chief Medical Officer -
Jeffrey Wayne Church,
VP, CFO, Treasurer & Corp. Sec -
Rahul Singhvi,
Sr VP, COO -
Thomas P Monath,
Director -
Elaine O'hara,
EVP, Chief Strategy Officer -
John C Jacobs,
President and CEO -
James Patrick Kelly,
EVP, CFO and Treasurer